Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDConduit Pharmaceuticals Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/13/2025 | Q4 2024 | N/A | $1.43 | N/A | N/A | $1.08 B |
| 10/31/2024 | Q3 2024 | N/A | $1.24 | N/A | N/A | $244.00 M |
| 08/12/2024 | Q2 2024 | N/A | -$0.15 | N/A | N/A | $604.34 M |
| 05/02/2024 | Q1 2024 | N/A | -$0.10 | N/A | N/A | $535.68 M |
| 12/30/2023 | Q4 2023 | N/A | $0.05 | N/A | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | $0.06 | N/A | N/A | $0 |
| 06/29/2023 | Q2 2023 | N/A | -$0.80 | N/A | N/A | $0 |
| 03/30/2023 | Q1 2023 | N/A | -$1.18 | N/A | N/A | $0 |
| 12/30/2022 | Q4 2022 | N/A | -$0.36 | N/A | N/A | $0 |
| 09/29/2022 | Q3 2022 | N/A | -$0.03 | N/A | N/A | $0 |
| 06/28/2022 | Q2 2022 | N/A | -$0.01 | N/A | N/A | $0 |
| 03/30/2022 | Q1 2022 | N/A | -$0.01 | N/A | N/A | $0 |
| 12/29/2021 | Q4 2021 | N/A | -$0.00 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Conduit Pharmaceuticals Inc. Earnings: FAQ's
Conduit Pharmaceuticals Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 18th, 2024 based offlast year's report dates.
The conference call for Conduit Pharmaceuticals Inc.'s latest earnings report can be listened to online.
The conference call transcript for Conduit Pharmaceuticals Inc.'s latest earnings report can be read online.
Conduit Pharmaceuticals Inc. (:CDT) has a recorded annual revenue of $2.46 B.
Conduit Pharmaceuticals Inc. (:CDT) has a recorded net income of $198.43 M.Conduit Pharmaceuticals Inc. has generated $4.88 earnings per share over the last four quarters.
Conduit Pharmaceuticals Inc. (:CDT) has a price-to-earnings ratio of 1.04 and price/earnings-to-growth ratio is 0.01.